Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...
GlobalData on MSN22h
Dyno and Roche collaborate on neurological gene therapiesDyno Therapeutics has formed a new research partnership with Roche, focusing on the development of next-generation ...
Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...
Our heart muscle is studded with tiny dyads, intricately designed structures that manage incoming electrical signals and ...
Conformational changes on the capsid may be the cause of the charge differences between empty and full AAV capsids.
After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...
With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...
George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...
Product launches is the main strategy followed by the manufacturers for insect cell lines market. On March 2020, Lonza has ...
GlobalData on MSN24d
The course to forging long-term manufacturing partnerships for gene therapiesThe 12th Annual Outsourcing in Clinical Trials & Clinical Trial Supply Nordics conference provided a venue to discuss the ...
Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of ...
Key Takeaways from the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Report DelveInsight’s Adeno-Associated Virus Vectors in Gene Therapy pipeline report depicts a robust space ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback